60 Degrees Pharmaceuticals (NASDAQ:SXTP) Announces Quarterly Earnings Results, Misses Expectations By $0.52 EPS

60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced its quarterly earnings results on Friday. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.52), FiscalAI reports. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.44 million.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ SXTP opened at $1.39 on Friday. The firm has a market cap of $3.67 million, a PE ratio of -0.10 and a beta of 2.69. 60 Degrees Pharmaceuticals has a one year low of $1.29 and a one year high of $14.68. The firm’s fifty day moving average is $1.82 and its two-hundred day moving average is $3.00.

Analysts Set New Price Targets

Several equities research analysts recently commented on SXTP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen lowered shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 12th. HC Wainwright lifted their price objective on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Ascendiant Capital Markets dropped their price objective on shares of 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $14.10.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.